Trevor Montano, a shareholder of Angel Oak Financial Strategies Income Term Trust, announced he will vote against two Class II Trustee nominees due to concerns about board entrenchment and governance issues. The trustees in question have served as holdovers despite not winning sufficient votes, and the board has not refreshed its independent trustees since inception. Additionally, the fund issued preferred shares granting a single investor the right to elect two trustees, removing those seats from common shareholders' vote. The fund's shares have traded at a discount to net asset value for over six years, an issue Montano believes the board should address. The annual shareholder meeting is set for September 25, 2026.
Kazia Therapeutics is progressing its main cancer drug candidate, paxalisib, into Phase 2 trials for colorectal cancer and planning a new breast cancer study. The company recently raised $40 million to support these developments and maintains a stron...
Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy ...
Duluth Holdings reported a strong Q2 earnings per share (EPS) of $0.50, far exceeding the consensus estimate of -$0.01, largely due to $0.44 per share from tariff refunds. Revenue reached $121.39 million, beating estimates but declining from the prev...
Estée Lauder Companies recently appointed new brand leaders, signaling strategic shifts in its competitive beauty market. An insider executive sold 7,766 shares worth over $802,000, leaving no remaining holdings. The company shows a high P/E ratio of...
HUTCHMED's shares surged 17.77% after announcing a major licensing deal with GSK for its preclinical cancer drug HMPL-A830. GSK gets exclusive rights outside Greater China, paying $110 million upfront plus up to $1.295 billion in milestone payments. ...
